胸腺退化
生物
胸腺瘤
胸腺癌
恶性转化
内卷(密宗)
癌变
胸腺细胞
舱室(船)
癌症研究
体细胞
T细胞
免疫学
免疫系统
癌症
神经科学
基因
遗传学
意识
地质学
海洋学
作者
Christopher S. Nabel,Jeanne B. Ackman,Yin P. Hung,Abner Louissaint,Gregory J. Riely
出处
期刊:Oncologist
[AlphaMed Press]
日期:2024-03-23
卷期号:29 (6): 473-483
被引量:4
标识
DOI:10.1093/oncolo/oyae046
摘要
Abstract Thymic epithelial tumors (TETs) are rare tumors for which treatment options are limited. The ongoing need for improved systemic therapies reflects a limited understanding of tumor biology as well as the normal thymus. The essential role of the thymus in adaptive immunity is largely effected by its epithelial compartment, which directs thymocyte (T-cell) differentiation and immunologic self-tolerance. With aging, the thymus undergoes involution whereby epithelial tissue is replaced by adipose and other connective tissue, decreasing immature T-cell production. Against this natural drive toward involution, a fraction of thymuses will instead undergo oncologic transformation, leading to the formation of TETs, including thymoma and thymic carcinoma. The rarity of these tumors restricts investigation of the mechanisms of tumorigenesis and development of rational treatment options. To this end, the development of technologies which allow deep molecular profiling of individual tumor cells permits a new window through which to view normal thymic development and contrast the malignant changes that result in oncogenic transformation. In this review, we describe the findings of recent illuminating studies on the diversity of cell types within the epithelial compartment through thymic differentiation and aging. We contextualize these findings around important unanswered questions regarding the spectrum of known somatic tumor alterations, cell of origin, and tumor heterogeneity. The perspectives informed by single-cell molecular profiling offer new approaches to clinical and basic investigation of thymic epithelial tumors, with the potential to accelerate development of improved therapeutic strategies to address ongoing unmet needs in these rare tumors.
科研通智能强力驱动
Strongly Powered by AbleSci AI